Forus Raises $160M+ to Attack Healthcare’s Administrative Black Hole

Forus, the New York-based healthcare infrastructure startup formerly known as Tandem, announced more than $160M in funding from Thrive Capital, General Catalyst, Accel, Bain Capital Ventures, Redpoint, BoxGroup, and Pear VC. The company is building an AI-powered network connecting doctors, pharmacies, payers, and biopharma companies to automate the administrative process between a prescription being written and a patient actually receiving treatment. That sounds clinical until you remember what healthcare administration in America actually feels like: endless insurance forms, prior authorizations that move slower than DMV lines during a flood warning, and doctors trapped inside workflows that seem engineered by people who hate both software and humanity equally.

Patients wait while treatments stall and drug makers lose visibility into what happens after approval. The system leaks time and money like a casino with broken plumbing, and Forus wants to become the connective tissue inside that chaos. The timing matters because enterprise AI is moving beyond “look what this model can generate” into “show me where the friction lives.” Investors are no longer throwing capital at AI wrappers with pretty demos and caffeine-fueled valuations. They are hunting infrastructure, workflow ownership, and embedded systems that quietly become impossible to remove once adoption compounds.

What Happened

Forus disclosed that it has raised more than $160M to expand its AI-powered healthcare network across the United States, with investors including Thrive Capital, General Catalyst, Accel, Bain Capital Ventures, Redpoint, BoxGroup, and Pear VC. The startup, previously operating as Tandem, is focused on automating the administrative chain connecting physicians, pharmacies, insurers, patients, and biopharma companies. According to the company, Forus embeds directly into physician workflows and handles tasks tied to prescription access, including insurance authorization, financial assistance, and fulfillment routing.

Forus says adoption has grown 10x year-over-year for the past 2 years, with the platform now used by thousands of medical practices and health systems across all 50 U.S. states and patient reach extending into nearly 80% of U.S. zip codes. The company also states that 5 of the top 10 global biopharma companies already work with the platform. That level of penetration matters more than flashy AI demos because enterprise software history is littered with products people applauded publicly and ignored privately. Workflow adoption tells the real story.

Why Healthcare Administration Became an AI Gold Mine

Healthcare administration has become one of the most economically irrational systems in modern business. America built world-class pharmaceutical innovation on top of administrative infrastructure that still occasionally behaves like a fax machine support group. The gap between “drug approved” and “patient treated” has become its own industry, with doctors spending enormous amounts of time navigating prior authorizations, insurance verification, specialty pharmacy coordination, and affordability programs.

Every additional administrative step introduces delay, confusion, and drop-off risk. For biopharma companies, that means patients eligible for treatment often never begin therapy at all. That operational dead space is where companies like Forus see opportunity, and the important distinction is that Forus is not positioning itself as another standalone AI application demanding behavior change from exhausted healthcare workers. The company is embedding itself directly into existing workflows, which changes the economics of adoption because infrastructure companies win quietly. Nobody celebrates plumbing until the water stops working.

Why Investors Are Piling Into Embedded AI Infrastructure

The broader AI market is entering a new phase. The first wave rewarded model access and rapid experimentation, while the second wave is rewarding companies that own operational surfaces inside major industries. That shift explains why firms like Thrive Capital, General Catalyst, and Accel are increasingly drawn toward infrastructure-layer AI businesses instead of consumer-facing novelty products.

Embedded workflow ownership creates defensibility because if an AI product becomes deeply integrated into prescription routing, insurance authorization, pharmacy coordination, and patient onboarding, replacing it becomes operationally painful. That creates stickiness investors care about far more than social media attention or short-term hype cycles. Forus also sits at the intersection of several large markets simultaneously: healthcare AI, enterprise workflow automation, life sciences infrastructure, payer coordination, and prescription access management. The biggest venture outcomes increasingly emerge from companies operating across fragmented ecosystems rather than inside narrow software categories.

Competitive Landscape

Forus is entering an increasingly crowded healthcare AI market, but the company’s positioning differs from many automation startups chasing administrative workflows. A large percentage of healthcare AI companies still focus on point solutions like documentation assistance, scheduling optimization, coding automation, or chatbot support. Those products solve isolated pain points, while Forus is attempting to build network infrastructure spanning multiple participants inside the treatment journey itself.

That distinction matters because networks compound. The more doctors, pharmacies, payers, and biopharma companies connected through the platform, the more visibility and process intelligence the system gains over time. Healthcare operators understand this instinctively because fragmentation creates inefficiency but also creates incumbency opportunities for companies capable of stitching disconnected systems together. That stitching process is ugly, slow, and bureaucratic work, which is exactly why venture firms continue funding it aggressively.

What This Signals About Enterprise AI

The Forus funding announcement reflects a broader reality emerging across enterprise AI markets: automation alone is no longer enough. Investors increasingly want systems capable of coordinating complex operational environments across multiple stakeholders, and that changes the profile of attractive startups. The next generation of AI winners may not look like media companies or consumer applications. They may look more like invisible infrastructure sitting underneath industries that still run on paperwork, disconnected systems, and human escalation chains.

Healthcare remains one of the richest opportunities because the friction is structural, not cosmetic. Forus is betting that the companies controlling operational coordination inside healthcare will become more valuable than companies simply generating information about it. That is a very different thesis than the early AI hype cycle and probably a much more durable one.

The Bigger Industry Shift

The deeper story underneath the Forus raise is not just healthcare automation. It is institutional trust in AI systems handling mission-critical operational work, and that threshold matters. Enterprise buyers no longer ask whether AI can generate output. They ask whether AI can reliably navigate complexity without creating new operational risk. That distinction separates infrastructure companies from demo companies.

The modern AI market is starting to resemble earlier cloud computing cycles because once the novelty wears off, buyers prioritize reliability, integration depth, workflow compatibility, and economic efficiency over theatrics. Healthcare just happens to be the sector where those pressures are loudest. Forus is stepping directly into that pressure zone with capital, momentum, and a market large enough to punish weak execution instantly, which in venture capital terms is usually where the interesting companies live.

Frequently Asked Questions

What is Forus?

Forus is a New York-based healthcare AI company building a network that connects doctors, pharmacies, payers, patients, and biopharma companies to automate prescription access workflows.

How much funding did Forus raise?

Forus announced that it raised more than $160M in funding.

Who invested in Forus?

Investors include Thrive Capital, General Catalyst, Accel, Bain Capital Ventures, Redpoint, BoxGroup, and Pear VC.

What does Forus automate?

Forus automates healthcare administrative workflows tied to treatment access, including insurance authorization, financial assistance, and prescription fulfillment routing.

How large is the Forus network?

Forus says its platform is used by thousands of medical practices and health systems across all 50 U.S. states and reaches nearly 80% of U.S. zip codes.

Why does the Forus funding matter?

The funding reflects growing investor interest in embedded AI infrastructure companies that own operational workflows inside large industries like healthcare.